A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
Items 301–400 of 572
Effect of Lysine at C-Terminus of the Dmt-Tic Opioid Pharmacophore
Balboni, G., Onnis, V., Congiu, C., Zotti, M., Sasaki, Y., Ambo, A., Bryant, S. D., Jinsmaa, Y., Lazarus, L. H., Trapella, C., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060741w · Cited by 25
Evidence-Based Treatments of Addiction
O’Brien, C. P. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.1.foc107 · Cited by 26
Self-citationQuetiapine for the treatment of alcoholism: Scientific rationale and review of the literature
Ray, L. A., Heydari, A., & Zorick, T. S. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00185.x · Cited by 27
Role of a Functional Human Gene Polymorphism in Stress Responsivity and Addictions
Mj, K. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.5 · Cited by 24
Setiawan, E., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.99 · Cited by 26
Ray, L. A., Hutchison, K. E., Ashenhurst, J. R., & Morrow, A. L. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01233.x · Cited by 24
Cannella, N., Ubaldi, M., Masi, A., Bramucci, M., Roberto, M., Bifone, A., & Ciccocioppo, R. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.014 · Cited by 26
“…studies in monkeys and in humans showed that naltrexone is not equally efficacious in all individuals treated and a link between the presence of A118G polymorphism at MOP opioid receptor locus (OPRM1) and drug efficacy was proposed (Anton et al., 2008; Barr et al., 2010; Oslin et al., 2003).”
BackgroundVerholleman, A., Victorri‐Vigneau, C., Laforgue, E., Derkinderen, P., Verstuyft, C., & Grall‐Bronnec, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083002 · Cited by 23
The response to naltrexone in ethanol-drinking rats depends on early environmental experiences
Daoura, L., & Nylander, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.004 · Cited by 23
“For example, several reports have shown that MOPR polymorphisms affect the response to naltrexone (Mague and Blendy, 2010; Oslin et al., 2003).”
BackgroundBoyd, K. N., Kumar, S., O’Buckley, T. K., & Morrow, A. L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06904.x · Cited by 22
“…naltrexone selectively increases serum 3a,5a-THP in heavy drinkers that harbor the mu opiate receptor polymorphism (Ray et al. 2010), a single nucleotide polymorphismmarker that has been associated with improved treatment response in several studies (Oslin et al. 2003; Anton et al. 2008).”
Johnson, B. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1065 · Cited by 22
“, to see a difference from placebo) being 7 for reducing the chance of relapse and 12 for reducing the chance of returning to drinking [6]; however, individuals with the Asp40 allele of the μ-opioid receptor, compared with those with the Asn40 allelic type, might derive greater therapeutic benefit than that observed f…”
BackgroundThe effects of naltrexone among alcohol non-abstainers: results from the COMBINE study
Ray, L. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00026 · Cited by 21
Yoon, G., Kim, S. W., THURAS, P. D., & Westermeyer, J. J. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1183 · Cited by 21
“…(1) prominent alcohol craving; (2) strong family history of alcohol problems (Monterosso et al., 2001); (3) increased metabolism of naltrexone; or (4) low response to standard-dose naltrexone secondary to gene polymorphism (Oslin et al., 2003) or opioid receptor up-regulation (McCaul et al., 2000).”
BackgroundThe Asp40 μ-Opioid Receptor Allele Does Not Predict Naltrexone Treatment Efficacy in Heavy Drinkers
Mitchell, J., Fields, H. L., White, R. L., Meadoff, T., Joslyn, G., & Rowbotham, M. C. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e68b0 · Cited by 21
Bergasa, N. V. (2014) · CRC Press eBooks · doi:10.1201/b16573-10 · Cited by 22
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders
Helton, S. G., & Lohoff, F. W. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.09.019 · Cited by 22
“However, Oslin et al. (2015) failed to find a significant genotype treatment interaction in their sample, suggesting that “it is premature to use the Asn40Asp polymorphism as a biomarker to predict the response to naltrexone treatment of alcohol dependence” (Oslin et al., 2015).”
BackgroundInfluentialImproving clinical outcomes for naltrexone as a management of problem alcohol use
Hulse, G. K. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04452.x · Cited by 23
Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists
van Rijn, R. M., Brissett, D. I., & Whistler, J. L. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.09.024 · Cited by 21
Pharmacologic treatment of alcoholism
Anton, R. F., Schacht, J. P., & Book, S. W. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00030-6 · Cited by 22
The importance of buprenorphine research in the opioid crisis
Pendergrass, S. A., Crist, R. C., Jones, L. K., Hoch, J. R., & Berrettini, W. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0329-5 · Cited by 23
Self-citationWorley, M. J., Witkiewitz, K. A., Brown, S. A., Kivlahan, D. R., & Longabaugh, R. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12605 · Cited by 22
“…Oroszi et al., 2009), including the μ-opioid receptor gene (OPRM1), with the Asp40 allele associated with greater naltrexone-induced blunting of alcohol reward (Ray and Hutchison, 2007; Setiawan et al., 2011) and stronger clinical response to naltrexone (Anton et al., 2008; Oslin et al., 2003).”
BackgroundChen, A. C. H., & Kuerbis, C. M. D. A. N. (2013) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000101 · Cited by 21
“[5] reported that a functional single nucleotide polymorphism (the A118G SNP, rs17799971, which encodes an Asn40Asp amino acid substitution) in exon 1 of the mu-opioid receptor gene (OPRM1), predicted the efficacy of naltrexone in reducing the likelihood of heavy drinking in alcohol dependent patients.”
BackgroundDelta Opioid Pharmacology in Relation to Alcohol Behaviors
Alongkronrusmee, D., Chiang, T., & van Rijn, R. M. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_30 · Cited by 21
“In humans a relatively common point mutation in the MOR gene (A118G/Asn40Asp) has been linked with affecting the effectiveness of Revia® (naltrexone) in treatment-seeking patients suffering from AUDs, although clinical evidence is not uniform (Gelernter et al. 2007; Oslin et al. 2003).”
BackgroundOpiate Receptors and Antagonists: From Bench to Clinic
Dean, R. L., Bilsky, E. J., & Negus, S. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0 · Cited by 24
Genetic disposition to addictive disorders — current knowledge and future perspectives
Mayer, P. E., & Höllt, V. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.009 · Cited by 20
Yuferov, V. P., Bart, G. B., & Kreek, M. J. (2005) · Nature Medicine · doi:10.1038/nm0105-23 · Cited by 22
Curley, J. P. (2011) · Behavioral Neuroscience · doi:10.1037/a0022939 · Cited by 19
“, 2008) and to be more sensitive to the euphoric effects of alcohol, more likely to abuse alcohol (Ray & Hutchison, 2004), and more likely to respond to treatment with naltrexone for alcoholism (Oslin et al., 2003; Ray & Hutchison, 2007).”
BackgroundLiu, M., & Park, S. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.08.013 · Cited by 20
Gegenhuber, B., Weinland, C., Kornhuber, J., Mühle, C., & Lenz, B. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.09.002 · Cited by 19
Krishnan‐Sarin, S., O’Malley, S. S., & Krystal, J. H. (2008) · Europe PMC (PubMed Central) · Cited by 19
Pettinati, H. M., Kampman, K. M., Lynch, K. G., Dundon, W. D., Mahoney, E. M., Wierzbicki, M. R., & O’Brien, C. P. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12146.x · Cited by 19
Self-citationNovel exonic μ‐opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence
Smith, R. J., Doyle, G. A. R., Han, A. M., Crowley, J. J., Oslin, D. W., Patkar, A. A., Mannelli, P., DeMaria, P. A., O’Brien, C. P., & Berrettini, W. H. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30105 · Cited by 19
“…receptor(s) with altered expression, structure, or function, which might lead to increased or decreased susceptibility to substance dependence [Bond et al., 1998; Koch et al., 2000; Befort et al., 2001; Wang et al., 2001], and influence treatment response to opioid antagonism [Oslin et al., 2003].”
BackgroundSelf-citationBjörk, K., Tronci, V., Thorsell, A., Tanda, G., Hirth, N., Heilig, M. A., Hansson, A. C., & Sommer, W. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3166-x · Cited by 22
“However, genetic factors have been shown to influence the response to medications used in the treatment of alcoholism, most notably exemplified by A118G variant in the human OPRM1 gene (Oslin et al. 2003; Ray and Hutchison 2007).”
Gene–environment interactions in addictive disorders: epidemiological and methodological aspects
Gorwood, P. A. P. M., Wohl, M., Strat, Y. L., & Rouillon, F. (2007) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2007.02.017 · Cited by 19
Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
Walker, L. C., & Lawrence, A. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1502269 · Cited by 22
“SNP in the OPRM1 gene (rs1799971) could be used to predict efficacy [142].”
BackgroundNeural Markers of Genetic Vulnerability to Drug Addiction
Müller, D. J., Likhodi, O., & Heinz, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_25 · Cited by 22
“(2003) reported the Asp40 allele of the mu-opioid receptor (OPRM1) gene to be associated with better response (lower relapse rates) to naltrexone (Oslin et al. 2003) – a finding that has recently been replicated (Anton et al.”
BackgroundOverstreet, D. H., Rezvani, A. H., Cowen, M. S., Chen, F., & Lawrence, A. J. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00033.x · Cited by 19
Johnson, B. A., Mann, K. F., Willenbring, M. L., Litten, R. Z., Swift, R. M., Lesch, O., & Berglund, M. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000174690.63787.fc · Cited by 19
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice
Ripley, T. L., Sanchez‐Roige, S., Bullmore, E. T., Mugnaini, M., Maltby, K., Miller, S. R., Willé, D. R., Nathan, P. J., & Stephens, D. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3995-x · Cited by 18
“…the therapeutic utility of naltrexone in alcohol dependence is limited, perhaps as a result of clinical and genetic heterogeneity: e.g. effects of naltrexone are stronger in the subgroup of alcoholic patients carrying the Asp variant of the mu-opioid receptor (OPRM1) A1118G SNP (Oslin et al. 2003).”
BackgroundLeménager, T., Hill, H., Reinhard, I., Hoffmann, S., Zimmermann, U. S., Hermann, D., Smolka, M. N., Kiefer, F., Vollstädt‐Klein, S., Heinz, A., et al. (2014) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.09.009 · Cited by 21
Korpi, E. R., Linden, A.-M., Hytönen, H. R., Paasikoski, N., Vashchinkina, E., Dudek, M., Herr, D. R., & Hyytiä, P. (2016) · Addiction Biology · doi:10.1111/adb.12393 · Cited by 18
“First, a specific variant of the polymorphic μ-opioid receptor (OPRM1 A118G) might be needed for increased efficacy for NTX (Oslin et al., 2003), although this has not been observed in all studies and not in the use of the second opioid antagonist approved for alcoholism, nalmefene (NMF) (Arias et…”
BackgroundSubstance Abuse is a Disease of the Human Brain: Focus on Alcohol
Anton, R. F. (2010) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2010.00527.x · Cited by 26
Novel Pharmacological Approaches to Drug Abuse Treatment
Edens, E. L., Massa, A. A., & Petrakis, I. L. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_29 · Cited by 23
“It has been proposed that individuals with the Asp variant of a m-opioid receptor (OPRM1) gene exhibit a greater response to opioid antagonist therapy (Oslin et al. 2003).”
BackgroundRinker, J. A., & Mulholland, P. J. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0193 · Cited by 19
Setting Priorities for Genomic Research
Berrettini, W. H., Bierut, L. J., Crowley, T. J., Cubells, J. F., Frascella, J., Gelernter, J. E., Hewitt, J. K., Kreek, M. J., Lachman, H., Leppert, M., et al. (2004) · Science · doi:10.1126/science.304.5676.1445c · Cited by 18
Self-citationZiauddeen, H., Nestor, L. J., Subramaniam, N., Dodds, C., Nathan, P. J., Miller, S. R., Sarai, B. K., Maltby, K., Fernando, D., Warren, L. L., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.60 · Cited by 20
“Initial findings of better treatment response to NTX in alcoholdependent G+ patients from post hoc analyses of clinical trial data (Anton et al, 2008; Oslin et al, 2003) have not been consistently replicated (Arias et al, 2006; Gelernter et al, 2007).”
BackgroundSebold, M., Garbusow, M., Cerci, D., Chen, K., Sommer, C., Huys, Q. J. M., Nebe, S., Rapp, M. A., Veer, I. M., Zimmermann, U. S., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991992 · Cited by 18
Potretzke, S., Zhang, Y., Li, J., Fecteau, K. M., Erikson, D. W., Hibert, M., & Ryabinin, A. E. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01490-3 · Cited by 17
Pathologic Gambling: Biological and Clinical Considerations
Topf, J. L., Yip, S. W., & Potenza, M. N. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31819b7bff · Cited by 18
Dahl, J. P., Doyle, G. A. R., OSLIN, D., Buono, R. J., Ferraro, T. N., Lohoff, F. W., & Berrettini, W. H. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.12.004 · Cited by 18
Self-citationPharmacogenetically Driven Treatments for Alcoholism: Are We There Yet?
Arias, A. J., & Sewell, R. A. (2012) · CNS Drugs · doi:10.2165/11633180-000000000-00000 · Cited by 22
Alcohol and the dopamine system
Söderpalm, B., & Ericson, M. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.02.003 · Cited by 22
Proudnikov, D., Randesi, M., Levran, O., Crystal, H., Dorn, M., Ott, J., Ho, A., & Kreek, M. J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis264 · Cited by 17
“the treatment of alcoholism [9].”
BackgroundHardin, J., He, Y., Javitz, H. S., Wessel, J., Krasnow, R. E., Tildesley, E. A., Hops, H., Swan, G. E., & Bergen, A. W. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0960 · Cited by 17
Convergent Balancing Selection on the Mu-Opioid Receptor in Primates
Sweeney, C. G., Rando, J. M., Panas, H. N., Miller, G. M., Platt, D. M., & Vallender, E. J. (2017) · Molecular Biology and Evolution · doi:10.1093/molbev/msx105 · Cited by 17
Alcohol addiction and the mu-opioid receptor
Berrettini, W. H. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.011 · Cited by 18
Self-citationCombining treatments for alcoholism: why and how?
Mattson, M. E., & Litten, R. Z. (2005) · Journal of Studies on Alcohol Supplement · doi:10.15288/jsas.2005.s15.8 · Cited by 18
Prospects for a Genomic Approach to the Treatment of Alcoholism
O’Brien, C. P. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.32 · Cited by 18
Self-citationWei, L. X., Floreani, A., Variola, A., Younis, C. M. E., & Bergasa, N. V. (2008) · Acta Dermato Venereologica · doi:10.2340/00015555-0436 · Cited by 17
Guerrin, C. G. J., Tesselaar, D. R. M., Booij, J., Schellekens, A., & Homberg, J. R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106311 · Cited by 16
“…> G variant (G carriers), have been associated with lower opioid receptor levels, which correlates with an increased relapse risk and may explain the reduced effectiveness of naltrexone in certain individuals (Hermann et al., 2017; Nielsen et al., 2014; Oslin et al., 2003; Taqi et al., 2019).”
Current Status of Co-Occurring Mood and Substance Use Disorders: A New Therapeutic Target
Pettinati, H. M., O’Brien, C. P., & Dundon, W. D. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130310 · Cited by 19
Self-citationOpioid Receptors Gene Polymorphism and Heroin Dependence in Iran
Asl, S. S., Roointan, A., Bergen, H., Amiri, S., Mardani, P., Ashtari, N., Shabani, R., & Mehdizadeh, M. (2018) · Basic and Clinical Neuroscience Journal · doi:10.29252/nirp.bcn.9.2.101 · Cited by 15
“…or function (which might result in receptors with altered expression) structured decrease or increase vulnerability to reliance on substance (Bond et al., 1998; Koch et al., 2000; Wang, Quillan, Winans, Lucas, & Sadée, 2001), and impact treatment response to opioid antagonists (Oslin et al., 2003).”
BackgroundDrug-Abuse Nanotechnology: Opportunities and Challenges
Mahmoudi, M., Pakpour, S., & Perry, G. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00127 · Cited by 14
Wong, C. J., Witcher, J., Mallinckrodt, C. H., Dean, R. A., Anton, R. F., Chen, Y.-F., Fijal, B. A., Ouyang, H., Dharia, S., Sundseth, S. S., et al. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12257 · Cited by 14
“Because genetics plays a critical role in the development of alcohol abuse (Schuckit, 2009) and possibly the response to naltrexone (Anton, 2008b; Oslin et al., 2003; Ray et al., 2012), DNA samples were collected.”
BackgroundGenetic Basis for Predicting Response to Naltrexone in the Treatment of Alcohol Dependence
Anton, R. F. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.6.655 · Cited by 14
Disulfiram in the management of alcohol dependence: A comprehensive clinical review
Kalra, G., Sousa, A. D., & Shrivastava, A. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.41007 · Cited by 40
“The functionally significant OPRM 1 Asp 40 allele predicts response to naltrexone treatment [87,88], whereas genetic variations in GATA4 genotype (GATA-binding protein 4) influences treatment response to acamprosate via modulation of atrial natriuretic polypeptide (ANP) plasma levels [89].”
Fongang, B., Cunningham, K. A., Rowicka, M., & Kudlicki, A. S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.05.013 · Cited by 14
Scarnati, M. S., Boreland, A. J., Joel, M., Hart, R. P., & Pang, Z. P. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.05.004 · Cited by 14
“Analysis of Gallele carriers diagnosed with an AUD responded more strongly to naltrexone, with lower rates of relapse and a longer time to return to heavy drinking (Oslin et al., 2003).”
BackgroundResultNaltrexone’s suppressant effects on drinking are limited to the first 3 months of treatment
Davidson, D., Wirtz, P. W., Gulliver, S. B., & Longabaugh, R. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0807-y · Cited by 15
“It is also possible that there are as yet unidentified patient characteristics, such as possessing certain genetic profiles that make naltrexone a more effective medication for some patients but not others (McGeary et al. 2006; Oslin et al. 2003).”
BackgroundPersonalized Addiction Treatment: How Close Are We?
Oslin, D. W. (2011) · Alcohol and Alcoholism · doi:10.1093/alcalc/agr030 · Cited by 14
“0% response) (Oslin et al., 2003).”
Self-citationOoteman, W., Verheul, R., Naassïla, M., Daoust, M., Schippers, G. M., Koeter, M. W. J., & van den Brink, W. (2005) · Journal of Substance Use · doi:10.1080/14659890500038764 · Cited by 18
“At the same time there are promising findings suggesting that genotypes have potential in terms of patient-treatment matching (Oslin et al., 2003) and unexplored endophenotypic indicators might have unknown predicting value.”
BackgroundResultHolstein, S. E., Pastor, R., Meyer, P., & Phillips, T. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0066-8 · Cited by 14
“Interestingly, the efficacy of naltrexone in the clinical treatment of alcoholism has suggested genotype dependence as well, specifically focusing on a polymorphism within the μ-opioid receptor gene (Oslin et al. 2003).”
BackgroundSustained-Release Naltrexone Formulations for the Treatment of Alcohol and Opioid Dependence
Volpicelli, J. R., & Fenton, M. C. (2006) · Future Neurology · doi:10.2217/14796708.1.4.389 · Cited by 14
“(2006) 1(4) those with a strong family history of alcohol use disorders or with a particular genetic marker may be particularly sensitive to the beneficial effects of naltrexone [15–18].”
BackgroundSelf-citationOpioid neuroscience for addiction medicine
Berrettini, W. H. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.030 · Cited by 14
Self-citationSubjective Response as a Consideration in the Pharmacogenetics of Alcoholism Treatment
Roche, D. J., & Ray, L. A. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.143 · Cited by 13
Patología dual en trastornos de ansiedad: recomendaciones en el tratamiento farmacológico
Sáiz, P. A., Treviño, L. J., Mesa, E. M. D., García‐Portilla, M. P., González, P. M., Al‐Halabí, S., Szerman, N., Bobes, J., & Ruiz, P. (2014) · Adicciones · doi:10.20882/adicciones.7 · Cited by 28
“…también apoyan esta relación, tras descubrirse cómo determinados polimorfismos implicados en la regulación del Eje HPA (Chong et al., 2006; Uhart, McCaul, Oswald, Choi y Wand, 2004; Wust et al., 2004) se asocian con la aparición de dependencia de alcohol (Oslin et al., 2003; Radel et al., 2005).”
Pal, R., Mendelson, J. E., Flower, K., Garrison, K. J., Yount, G. L., Coyle, J., & Galloway, G. P. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000107 · Cited by 14
“Oslin et al. (2003) pooled data from 3 clinical trials and found that alcoholdependent subjects who were A118G hetero- or homozygous had an enhanced response to naltrexone (significantly lower rates of relapse and a longer time to return to heavy drinking).”
BackgroundPharmacogenetics of alcohol addiction: current perspectives
Zastrozhin, M. S., Skryabin, V. Y., Miroshkin, S., Bryun, E. A., & Sychev, D. A. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s206745 · Cited by 15
Lin, Y., Kranzler, H. R., Farrer, L. A., Xu, H., Henderson, D. C., & Zhang, H. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0158-1 · Cited by 15
Self-citationAlcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence
García, M. L. G., Blasco-Algora, S., & Fernández-Rodríguez, C. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i28.8516 · Cited by 13
Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome
McLemore, G. L., Lewis, T. R., Jones, C. H., & Gauda, E. B. (2012) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2012.09.002 · Cited by 16
Genetics and Alcoholism: How Close are We to Potential Clinical Applications?
Quickfall, J., & el‐Guebaly, N. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100708 · Cited by 21
What Aspects of Human Alcohol Use Disorders Can Be Modeled Using Selectively Bred Rat Lines?
Froehlich, J. C. (2010) · Substance Use & Misuse · doi:10.3109/10826084.2010.482424 · Cited by 13
“For instance, the mu opioid receptor gene (OPR1) has a polymorphism and people with the Asp40 allele respond better to naltrexone with a lower rate of relapse and a longer time to return to heavy drinking compared with people with the Asn40 allele (Oslin et al., 2003).”
Backgroundde Bejczy, A., & Söderpalm, B. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000259 · Cited by 14
Alcohol addiction: toward a patient-oriented pharmacological treatment
Addolorato, G., Mirijello, A., & Leggio, L. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.834047 · Cited by 13
Opioid Pharmacogenetics of Alcohol Addiction
Berrettini, W. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1093/acprof:oso/9780199655786.003.0011 · Cited by 15
Self-citationWhat is known about treatment aimed at indigenous people suffering from alcohol use disorder?
Andersen, L. A. K., Munk, S., Nielsen, A. S., & Bilberg, R. (2019) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2019.1679317 · Cited by 18
“It has been discussed whether having a G-allele in the OPRM1 gene affected the drug response of naltrexone (Anton et al., 2008; O’Malley et al., 2008; Oslin et al., 2003).”
BackgroundAnton, R. F., Voronin, K. E., Book, S. W., Latham, P. K., Randall, P. K., Glen, W. B., Hoffman, M., & Schacht, J. P. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14431 · Cited by 12
“Assessment and Medical Management (MM)—Medical management (MM), a manualized intervention (Pettinati et al., 2005) designed and used previously (Anton et al., 2006), and also utilized in previous naltrexone pharmacogenetic studies (Oslin et al., 2003, Anton et al., 2008) was administered.”
BackgroundMethodTarli, C., Mirijello, A., & Addolorato, G. (2022) · Seminars in Liver Disease · doi:10.1055/a-1798-2872 · Cited by 12
Ambulatory Monitoring in the Genetics of Psychosomatic Medicine
Finan, P. H., Tennen, H. A., Thoemmes, F. J., Zautra, A., & Davis, M. C. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182544a74 · Cited by 15
Update on the Pharmacological Treatment of Pathological Gambling
Bullock, S. A., & Potenza, M. N. (2014) · Current Psychopharmacologye · doi:10.2174/22115560113029990008 · Cited by 12
Pharmacogenomics in Psychiatric Practice.
El-Mallakh, R., Roberts, R. J., El-Mallakh, P., Findlay, L. J., & Reynolds, K. K. (2016) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2016.05.001 · Cited by 14
Cottencin, O., Guardia, D., Karila, L., & Rolland, B. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.07.032 · Cited by 14
Blackwood, C. A., & Cadet, J. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.798362 · Cited by 12
Collins, D., Zhang, Y., Blendy, J. A., & Kreek, M. J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107864 · Cited by 11
Gioia, D. A., & McCool, B. A. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13343 · Cited by 12
“For example, of the few available pharmacological treatments, efficacy has often been linked with specific genetic mutations including Naltrexone (OPRM1), Acamprosate (GRIN2B), and Topiramate (GRIK1) (Karpyak et al., 2014; Kranzler et al., 2014; Oslin et al., 2003).”
Preclinical evidence of new opioid modulators for the treatment of addiction
Rodríguez‐Arias, M., Aguilar, M. A., Manzanedo, C., & Miñarro, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.500612 · Cited by 12
Batki, S. L., & Pennington, D. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010061 · Cited by 11
Henderson, A. N., Lowe, T. E., Tian, X., & Morgan, D. J. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.017 · Cited by 10
“Likewise, while some clinical studies show that alcoholics with at least one copy of the G allele are more responsive to naltrexone treatment (Oslin et al., 2003; Bart et al., 2005; Arias et al., 2006; Chamorro et al., 2012) others find that they are not (Gelernter et al., 2007; Tidey et al., 2008;…”
InfluentialContextual processing and its alterations in patients with addictive disorders
Elman, I., Ariely, D., Tsoy-Podosenin, M., Verbitskaya, E., Wahlgren, V., Wang, A., Zvartau, E. E., Borsook, D., & Krupitsky, E. M. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100100 · Cited by 15
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.